The principal effect of our derivative instruments designated in cash flow hedging relationships on our results of operations, as well as OCI, net of income tax effect, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Instruments in Designated Cash Flow Hedging Relationships |
|
Net Gain (Loss) Recognized in OCI |
|
Location of Net Gain (Loss) Reclassified from AOCI to Income (Loss) |
|
Net Gain (Loss) Reclassified from AOCI to Income (Loss) |
(in millions) |
|
|
|
|
|
|
For the Nine Months Ended November 30, 2023 |
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
177.1 |
|
|
Sales |
|
$ |
(0.2) |
|
|
|
|
|
Cost of product sold |
|
102.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-issuance hedge contracts |
|
0.5 |
|
|
Interest expense |
|
(0.4) |
|
|
|
$ |
177.6 |
|
|
|
|
$ |
101.7 |
|
|
|
|
|
|
|
|
For the Nine Months Ended November 30, 2022 |
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
146.6 |
|
|
Sales |
|
$ |
(1.4) |
|
|
|
|
|
Cost of product sold |
|
34.0 |
|
|
|
|
|
|
|
|
Pre-issuance hedge contracts |
|
15.7 |
|
|
Interest expense |
|
(0.8) |
|
|
|
$ |
162.3 |
|
|
|
|
$ |
31.8 |
|
|
|
|
|
|
|
|
For the Three Months Ended November 30, 2023 |
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
27.2 |
|
|
Sales |
|
$ |
— |
|
|
|
|
|
Cost of product sold |
|
36.6 |
|
|
|
|
|
|
|
|
Pre-issuance hedge contracts |
|
(0.1) |
|
|
Interest expense |
|
(0.1) |
|
|
|
$ |
27.1 |
|
|
|
|
$ |
36.5 |
|
|
|
|
|
|
|
|
For the Three Months Ended November 30, 2022 |
|
|
|
|
|
|
Foreign currency contracts |
|
$ |
75.3 |
|
|
Sales |
|
$ |
(0.2) |
|
|
|
|
|
Cost of product sold |
|
12.1 |
|
|
|
|
|
|
|
|
Pre-issuance hedge contracts |
|
— |
|
|
Interest expense |
|
(0.2) |
|
|
|
$ |
75.3 |
|
|
|
|
$ |
11.7 |
|
The effect of our undesignated derivative instruments on our results of operations is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Instruments Not Designated as Hedging Instruments |
|
|
|
Location of Net Gain (Loss) Recognized in Income (Loss) |
|
Net Gain (Loss) Recognized in Income (Loss) |
(in millions) |
|
|
|
|
|
|
For the Nine Months Ended November 30, 2023 |
|
|
|
|
|
|
Commodity derivative contracts |
|
|
|
Cost of product sold |
|
$ |
(28.9) |
|
Foreign currency contracts |
|
|
|
Selling, general, and administrative expenses |
|
12.7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(16.2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Instruments Not Designated as Hedging Instruments |
|
|
|
Location of Net Gain (Loss) Recognized in Income (Loss) |
|
Net Gain (Loss) Recognized in Income (Loss) |
(in millions) |
|
|
|
|
|
|
For the Nine Months Ended November 30, 2022 |
|
|
|
|
|
|
Commodity derivative contracts |
|
|
|
Cost of product sold |
|
$ |
25.3 |
|
Foreign currency contracts |
|
|
|
Selling, general, and administrative expenses |
|
(11.9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
13.4 |
|
|
|
|
|
|
|
|
For the Three Months Ended November 30, 2023 |
|
|
|
|
|
|
Commodity derivative contracts |
|
|
|
Cost of product sold |
|
$ |
(13.3) |
|
Foreign currency contracts |
|
|
|
Selling, general, and administrative expenses |
|
(9.8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(23.1) |
|
|
|
|
|
|
|
|
For the Three Months Ended November 30, 2022 |
|
|
|
|
|
|
Commodity derivative contracts |
|
|
|
Cost of product sold |
|
$ |
(7.8) |
|
Foreign currency contracts |
|
|
|
Selling, general, and administrative expenses |
|
(9.3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
(17.1) |
|
|